Stocktoria
IRIDEX CORP IRIX
Nasdaq · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 1996-02-16
IRIDEX CORP financials (annual)
Bars are annual figures from 2016 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.7M | $48.7M | $51.9M | $57.0M | $53.9M | $36.3M | $43.4M | $42.6M | $41.6M | $46.2M |
| Gross profit | $19.2M | $19.5M | $21.8M | $25.4M | $22.8M | $15.6M | $17.9M | $17.5M | $15.5M | $20.8M |
| R&D expense | $3.7M | $5.4M | $6.8M | $7.2M | $6.9M | $3.3M | $3.7M | $4.0M | $5.2M | $5.4M |
| Operating income | -$2.6M | -$8.3M | -$10.0M | -$7.5M | -$7.5M | -$6.6M | -$9.0M | -$12.9M | -$12.9M | -$2.6M |
| Income tax | $57,000 | $68,000 | $90,000 | $65,000 | $40,000 | $26,000 | $48,000 | $37,000 | -$128,000 | $9.1M |
| Net income | -$4.4M | -$8.9M | -$9.6M | -$7.5M | -$5.2M | -$6.3M | -$8.8M | -$12.8M | -$12.9M | -$11.7M |
| EPS (diluted) | $-0.26 | $-0.54 | $-0.59 | $-0.47 | $-0.34 | $-0.46 | $-0.64 | $-1.05 | $-1.11 | $-1.15 |
| Operating cash flow | -$2.1M | -$7.3M | -$6.7M | -$9.5M | $8.2M | -$3.2M | -$7.9M | -$10.0M | -$3.6M | -$144,000 |
| Free cash flow | -$2.3M | -$7.3M | -$6.9M | -$9.8M | $8.0M | -$3.3M | -$8.0M | -$10.5M | -$4.1M | -$1.2M |
| Cash & equivalents | $6.0M | $2.4M | $7.0M | $13.9M | $23.9M | $11.6M | $12.7M | $21.2M | $21.7M | $23.7M |
| Inventory | $7.9M | $10.8M | $9.9M | $10.6M | $7.6M | $5.7M | $8.2M | $8.8M | $9.4M | $11.6M |
| Total assets | $29.2M | $29.1M | $34.4M | $42.3M | $48.7M | $28.0M | $34.8M | $41.7M | $41.6M | $48.1M |
| Total liabilities | $24.2M | $27.0M | $24.9M | $25.1M | $25.4M | $10.6M | $12.1M | $11.7M | $11.1M | $9.0M |
| Shareholders' equity | $4.9M | $2.1M | $9.5M | $17.2M | $23.3M | $17.4M | $22.7M | $30.0M | $30.5M | $39.2M |
Growth · year-over-year · Revenue CAGR 1.5%
| Metric | FY2026 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +8.2% | -6.2% | -9.0% | +5.7% | +48.3% | -16.3% | +2.0% | +2.4% | -9.9% | +10.5% |
| Net income growth | — | — | — | — | — | — | — | — | — | -2571.1% |
| EPS growth | — | — | — | — | — | — | — | — | — | -2400.0% |
| Free cash flow growth | — | — | — | -222.5% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-01-03. Facts plus Stocktoria's own computed scores — not investment advice.